Viaderma Inc
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as w… Read more
Viaderma Inc (VDRM) - Net Assets
Latest net assets as of September 2024: $-144.40K USD
Based on the latest financial reports, Viaderma Inc (VDRM) has net assets worth $-144.40K USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.07 Million) and total liabilities ($4.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-144.40K |
| % of Total Assets | -3.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 57.86 |
Viaderma Inc - Net Assets Trend (2008–2023)
This chart illustrates how Viaderma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Viaderma Inc (2008–2023)
The table below shows the annual net assets of Viaderma Inc from 2008 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $123.15K | +106.68% |
| 2022-12-31 | $-1.84 Million | +24.26% |
| 2021-12-31 | $-2.44 Million | -11.31% |
| 2020-12-31 | $-2.19 Million | +26.97% |
| 2019-12-31 | $-3.00 Million | -10.13% |
| 2018-12-31 | $-2.72 Million | -158.81% |
| 2017-12-31 | $-1.05 Million | -266.48% |
| 2016-12-31 | $-286.81K | +48.22% |
| 2015-12-31 | $-553.90K | +39.91% |
| 2014-12-31 | $-921.74K | -102.75% |
| 2011-12-31 | $33.56 Million | +14.90% |
| 2010-12-31 | $29.21 Million | +24.53% |
| 2009-12-31 | $23.45 Million | +186373.00% |
| 2008-12-31 | $-12.59K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viaderma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1346561300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $123.37K | 100.18% |
| Other Comprehensive Income | $-123.37K | -100.18% |
| Other Components | $13.73 Million | 11149.21% |
| Total Equity | $123.15K | 100.00% |
Viaderma Inc Competitors by Market Cap
The table below lists competitors of Viaderma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
H&G High Conviction Ltd
AU:HCF
|
$180.31 |
|
Nusantara Inti Corpora Tbk
JK:UNIT
|
$180.42 |
|
KLONDIKE SILVER
BE:K1SN
|
$180.79 |
|
Vista Land and Lifescapes Inc
PSE:VLL
|
$181.11 |
|
PLD CORPORATION
BE:P8O
|
$179.47 |
|
UNIVERSAL PARTNERS LTD (GBP)
SEM:UPL
|
$179.07 |
|
Dost Steels Ltd
KAR:DSL
|
$179.00 |
|
TIANJIN JINRAN -H-
BE:TL6
|
$178.91 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viaderma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -1,844,506 to 123,150, a change of 1,967,656.
- Net income of 4,097 contributed positively to equity growth.
- Other comprehensive income decreased equity by 25,015.
- Other factors increased equity by 1,988,574.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.10K | +3.33% |
| Other Comprehensive Income | $-25.02K | -20.31% |
| Other Changes | $1.99 Million | +1614.76% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Viaderma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 246.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 22.64x to 246.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.00 | $0.02 | x |
| 2008-12-31 | $0.00 | $0.02 | x |
| 2009-12-31 | $0.17 | $0.02 | x |
| 2010-12-31 | $0.21 | $0.02 | x |
| 2011-12-31 | $0.24 | $0.02 | x |
| 2015-12-31 | $-0.01 | $0.02 | x |
| 2016-12-31 | $0.00 | $0.02 | x |
| 2017-12-31 | $0.00 | $0.02 | x |
| 2018-12-31 | $0.00 | $0.02 | x |
| 2019-12-31 | $0.00 | $0.02 | x |
| 2020-12-31 | $0.00 | $0.02 | x |
| 2021-12-31 | $0.00 | $0.02 | x |
| 2022-12-31 | $0.00 | $0.02 | x |
| 2023-12-31 | $0.00 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viaderma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.68%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 10.40x
- Recent ROE (3.33%) is above the historical average (-101.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -1564.40% | -787.86% | 1.99x | 1.00x | $-142.39K |
| 2008 | 0.00% | -119.99% | 2.55x | 0.00x | $-17.82K |
| 2009 | 17.46% | 16.21% | 0.84x | 1.28x | $1.75 Million |
| 2010 | 15.43% | 16.80% | 0.74x | 1.24x | $1.59 Million |
| 2011 | 7.96% | 14.06% | 0.45x | 1.27x | $-683.19K |
| 2014 | 0.00% | -4947.10% | 10.49x | 0.00x | $-6.38 Million |
| 2015 | 0.00% | 14.14% | 1.09x | 0.00x | $82.51K |
| 2016 | 0.00% | -48.34% | 0.65x | 0.00x | $-93.13K |
| 2017 | 0.00% | -3397.52% | 0.10x | 0.00x | $-1.41 Million |
| 2018 | 0.00% | -6521.27% | 0.81x | 0.00x | $-2.73 Million |
| 2019 | 0.00% | -5764.98% | 0.15x | 0.00x | $-299.68K |
| 2020 | 0.00% | -3764.15% | 0.09x | 0.00x | $-212.89K |
| 2021 | 0.00% | -193.42% | 1.87x | 0.00x | $-750.66K |
| 2022 | 0.00% | 109.25% | 0.76x | 0.00x | $775.12K |
| 2023 | 3.33% | 0.68% | 0.47x | 10.40x | $-8.22K |
Industry Comparison
This section compares Viaderma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viaderma Inc (VDRM) | $-144.40K | -1564.40% | N/A | $179.93 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |